Abbott Labs (ABT) Share Price Rose While Sand Hill Global Advisors LLC Has Decreased Position by $3.92 Million

July 13, 2018 - By Sonya McDaniel

Abbott Laboratories (NYSE:ABT) LogoInvestors sentiment decreased to 0.83 in Q1 2018. Its down 0.08, from 0.91 in 2017Q4. It worsened, as 44 investors sold ABT shares while 606 reduced holdings. 126 funds opened positions while 411 raised stakes. 1.22 billion shares or 0.54% more from 1.22 billion shares in 2017Q4 were reported. Oarsman Cap has 11,333 shares for 0.31% of their portfolio. Pura Vida Invests Limited holds 60,500 shares. Rmsincerbeaux Cap Mngmt Llc holds 1.51% of its portfolio in Abbott Laboratories (NYSE:ABT) for 26,850 shares. The Wisconsin-based North Star Asset Management Inc has invested 1.48% in Abbott Laboratories (NYSE:ABT). Moreover, Clark Cap Gru has 0.03% invested in Abbott Laboratories (NYSE:ABT) for 13,522 shares. Voya Investment Mngmt Ltd Liability Corp owns 774,452 shares. The North Carolina-based Kdi Cap Prtn Ltd has invested 3.45% in Abbott Laboratories (NYSE:ABT). Private Ocean Ltd holds 0.06% in Abbott Laboratories (NYSE:ABT) or 2,193 shares. Boston Private Wealth Ltd Liability Company holds 1.23% in Abbott Laboratories (NYSE:ABT) or 536,293 shares. Jfs Wealth Lc holds 2,801 shares or 0.04% of its portfolio. Adell Harriman & Carpenter Inc invested in 0% or 7,033 shares. Valley Natl Advisers holds 0.26% or 11,471 shares in its portfolio. South Texas Money Ltd owns 10,769 shares or 0.03% of their US portfolio. Oppenheimer Asset Mngmt has 379,423 shares. D Scott Neal accumulated 0.05% or 1,453 shares.

Since January 30, 2018, it had 1 insider purchase, and 20 selling transactions for $22.32 million activity. $84,344 worth of Abbott Laboratories (NYSE:ABT) shares were sold by MANNING JOSEPH J. On Wednesday, February 28 Bracken Sharon J sold $62,056 worth of Abbott Laboratories (NYSE:ABT) or 1,053 shares. Another trade for 227,412 shares valued at $14.27M was made by Fussell Stephen R on Tuesday, January 30. $27,213 worth of Abbott Laboratories (NYSE:ABT) shares were sold by PEDERSON MICHAEL J. Salvadori Daniel Gesua Sive sold $183,592 worth of stock. STARKS DANIEL J bought $2.43 million worth of stock.

Sand Hill Global Advisors Llc decreased its stake in Abbott Labs (ABT) by 85.79% based on its latest 2018Q1 regulatory filing with the SEC. Sand Hill Global Advisors Llc sold 66,444 shares as the company’s stock rose 3.04% while stock markets declined. The institutional investor held 11,006 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $659,000, down from 77,450 at the end of the previous reported quarter. Sand Hill Global Advisors Llc who had been investing in Abbott Labs for a number of months, seems to be less bullish one the $110.56 billion market cap company. The stock increased 0.51% or $0.32 during the last trading session, reaching $63.06. About 5.09M shares traded. Abbott Laboratories (NYSE:ABT) has risen 41.91% since July 13, 2017 and is uptrending. It has outperformed by 29.34% the S&P500.

Analysts await Abbott Laboratories (NYSE:ABT) to report earnings on July, 18 before the open. They expect $0.71 earnings per share, up 14.52 % or $0.09 from last year’s $0.62 per share. ABT’s profit will be $1.24B for 22.20 P/E if the $0.71 EPS becomes a reality. After $0.59 actual earnings per share reported by Abbott Laboratories for the previous quarter, Wall Street now forecasts 20.34 % EPS growth.

Another recent and important Abbott Laboratories (NYSE:ABT) news was published by Streetinsider.com which published an article titled: “Abbott (ABT) Announces FDA Approval for Next-Generation MitraClip Device to Treat People with Leaky Heart Valves” on July 12, 2018.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

Among 14 analysts covering Abbott Laboratories (NYSE:ABT), 12 have Buy rating, 0 Sell and 2 Hold. Therefore 86% are positive. Abbott Laboratories had 16 analyst reports since January 22, 2018 according to SRatingsIntel. The firm has “Overweight” rating given on Thursday, January 25 by JP Morgan. The stock has “Buy” rating by BMO Capital Markets on Wednesday, January 24. The rating was maintained by Jefferies on Wednesday, April 18 with “Buy”. The rating was maintained by Wells Fargo on Thursday, January 25 with “Outperform”. The stock has “Overweight” rating by Morgan Stanley on Thursday, January 25. RBC Capital Markets maintained Abbott Laboratories (NYSE:ABT) rating on Wednesday, January 24. RBC Capital Markets has “Buy” rating and $67.0 target. The stock has “Buy” rating by Stifel Nicolaus on Wednesday, January 24. The stock of Abbott Laboratories (NYSE:ABT) has “Neutral” rating given on Monday, January 22 by BTIG Research. The firm has “Buy” rating given on Wednesday, January 24 by Jefferies. As per Tuesday, January 30, the company rating was maintained by Citigroup.

Abbott Laboratories (NYSE:ABT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.